{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:48:22Z","timestamp":1780530502097,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Fondo de Investigaciones Sanitarias","award":["PI12\/00840"],"award-info":[{"award-number":["PI12\/00840"]}]},{"name":"Spanish Fondo de Investigaciones Sanitarias","award":["PI15\/00716"],"award-info":[{"award-number":["PI15\/00716"]}]},{"name":"Spanish Fondo de Investigaciones Sanitarias","award":["PI15\/00956"],"award-info":[{"award-number":["PI15\/00956"]}]},{"name":"Spanish Fondo de Investigaciones Sanitarias","award":["CM17\/00042"],"award-info":[{"award-number":["CM17\/00042"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Development Regional Fund"},{"name":"Catalan Government","award":["AGAUR 2014_SGR_603"],"award-info":[{"award-number":["AGAUR 2014_SGR_603"]}]},{"name":"CERCA Programme\/Generalitat de Catalunya"},{"name":"European Commission under the 6th Framework Programme","award":["LSHC-CT-2006-018,702"],"award-info":[{"award-number":["LSHC-CT-2006-018,702"]}]},{"name":"European Commission under the 7th Framework Programme"},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 La Marat\u00f3 de TV3","doi-asserted-by":"crossref","award":["201,331\u201330"],"award-info":[{"award-number":["201,331\u201330"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Todos somos raros"},{"name":"Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer"},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Department of Dermatology of the Instituto Valenciano de Oncolog\u00eda"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.11.036","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T02:59:57Z","timestamp":1610161197000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-3444","authenticated-orcid":false,"given":"Alicia","family":"Barreiro-Capurro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-4752","authenticated-orcid":false,"given":"Juan J.","family":"Andr\u00e9s-Lencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-0522","authenticated-orcid":false,"given":"Sebastian","family":"Podlipnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-8820","authenticated-orcid":false,"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-4169","authenticated-orcid":false,"given":"Celia","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-5314","authenticated-orcid":false,"given":"Esperanza","family":"Manrique-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-554X","authenticated-orcid":false,"given":"Luca","family":"Tonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2699-1159","authenticated-orcid":false,"given":"Ane","family":"Jaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-8769","authenticated-orcid":false,"given":"Nina","family":"Richarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-7153","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Rodr\u00edguez-Peralto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-9639","authenticated-orcid":false,"given":"Pablo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9809-5308","authenticated-orcid":false,"given":"Aram","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3433-8707","authenticated-orcid":false,"given":"Eduardo","family":"Nagore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-914X","authenticated-orcid":false,"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-9745","authenticated-orcid":false,"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.036_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.11.036_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.11.036_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamadermatol.2016.4512","article-title":"Analysis of trends in US melanoma incidence and mortality","volume":"153","author":"Glazer","year":"2017","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.ejca.2020.11.036_bib4","series-title":"AJCC cancer staging man","first-page":"563","article-title":"Melanoma of the skin","author":"Gershenwald","year":"2017"},{"key":"10.1016\/j.ejca.2020.11.036_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.sder.2010.06.004","article-title":"Implications of the 2009 American Joint committee on cancer melanoma staging and classification on dermatologists and their patients","volume":"29","author":"Nading","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.ejca.2020.11.036_bib6","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2020.11.036_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2020.11.036_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jclinpath-2018-205417","article-title":"Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters","volume":"72","author":"Trinidad","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ejca.2020.11.036_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-22539-5_5","article-title":"Principles of melanoma staging","volume":"167","author":"Boland","year":"2016","journal-title":"Canc Treat Res"},{"key":"10.1016\/j.ejca.2020.11.036_bib10","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma corresponding authors","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib14","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/path.1365","article-title":"The development of optimal pathological assessment of sentinel lymph nodes for melanoma","volume":"200","author":"Cook","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2020.11.036_bib19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib20","series-title":"survminer: drawing Survival Curves using \u201cggplot2\u201d","author":"Kassambara","year":"2019"},{"key":"10.1016\/j.ejca.2020.11.036_bib21","series-title":"A package for survival analysis in S","author":"Therneau","year":"2015"},{"key":"10.1016\/j.ejca.2020.11.036_bib22","series-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.ejca.2020.11.036_bib23","series-title":"A language and environment for statistical computing","year":"2019"},{"key":"10.1016\/j.ejca.2020.11.036_bib24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib25","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1002\/cam4.2358","article-title":"Survival analysis and sentinel lymph node status in thin cutaneous melanoma: a multicenter observational study","volume":"8","author":"Tejera-Vaquerizo","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2020.11.036_bib26","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1245\/s10434-016-5137-z","article-title":"Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis","volume":"23","author":"Cordeiro","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib27","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","article-title":"Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma","volume":"31","author":"Han","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/SLA.0b013e3182306c72","article-title":"Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma","volume":"255","author":"Murali","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2020.11.036_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CMR.0000000000000643","article-title":"External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?","volume":"30","author":"Madu","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2020.11.036_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/fon-2018-0671","article-title":"Stage III melanoma incidence and impact of transitioning to\u00a0the 8th AJCC staging system: a US population-based study","volume":"15","author":"Tarhini","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","article-title":"Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma","volume":"119","author":"Kanaki","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.036_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2017.11.023","article-title":"Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III","volume":"91","author":"Grob","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.036_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2217\/fon-2017-0500","article-title":"Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin","volume":"14","author":"Abdel-Rahman","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.036_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jdv.15454","article-title":"Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study","volume":"33","author":"Podlipnik","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2020.11.036_bib36","first-page":"791","article-title":"Gene expression profiling in melanoma: past results and future potential","volume":"15","author":"Knackstedt","year":"2019","journal-title":"Future\u00a0Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","volume":"125","author":"Amaral","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.036_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz255.054","article-title":"1366PEvaluating polygenic risk score prediction model for melanoma prognosis","volume":"30","author":"Potrony","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.036_bib39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ijc.31780","article-title":"TERT promoter mutation subtypes and survival in stage I and II melanoma patients","volume":"144","author":"Andr\u00e9s-Lencina","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.11.036_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.30042","article-title":"TERT promoter mutations in melanoma survival","volume":"139","author":"Nagore","year":"2016","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.11.036_bib41","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.18632\/oncotarget.26688","article-title":"TERT promoter mutations in melanoma survival","volume":"10","author":"Nagore","year":"2019","journal-title":"Oncotarget"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:29Z","timestamp":1760732969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":41,"alternative-id":["S0959804920313733"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}